Saturday, October 16, 2021

Evotec starts work on $240M French companion to its biologics ‘facility of the future’ in Washington

A little over a year after Evotec’s U.S. subsidiary started work on its biologics “facility of the future” in Washington, the German biotech-CRO hybrid has unveiled plans to stand up a sister facility in France. 

Evotec has kicked off construction on a new biologics factory in Toulouse dubbed J.POD 2 EU, the company said Tuesday. The French government, investment bank Bpifrance, the city of Toulouse and more will chip in up to €50 million ($60.18 million) for the project. Evotec plans to invest around €150 million ($180.53 million).

The site will be the company’s second to leverage its speedy and continuous bioprocessing approach and Evotec’s first commercial plant in Europe.

Evotec hopes the new space in France will beef up “nearshore” biomanufacturing capacity, CEO Werner Lanthaler said in a release. That should prove especially useful in the ongoing fight against COVID-19, as well future pandemics, the company added. Plus, Evotec’s flexible J.POD plants can be fitted with extra cleanroom PODS for quick and easy scale-up.

Over the past year, the company’s biologics subsidiary Just has tied up with Ology Bioservices—recently acquired by fledgling manufacturer National Resilience—and won cash from the U.S. Department of Defense and the Bill & Melinda Gates Foundation to seek out and produce new monoclonal antibody drugs to help combat COVID-19.

RELATED: Feds halt Eli Lilly’s solo antibody rollout in 3 states on worries about local coronavirus variant

Evotec will deploy its biologics subsidiary’s continuous manufacturing approach at the French plant. Just’s “intensified” bioprocessing—which strives to get more product out of the manufacturing process—takes place inside compact and autonomous cleanrooms called J.PODS. That process saves overall manufacturing space and allows for easier scale-up and deployment, Just says.

Evotec expects the site to be fully operational in 2023. Evotec didn’t say how big the new facility would be nor how many employees it plans to staff there. The company didn’t immediately respond to Fierce Pharma’s request for comment.

RELATED: Fledgling CDMO Lakes BioScience blueprints $490M antibody factory at ex-GlaxoSmithKline site

Meanwhile, Just is also building a new site in Redmond, Washington, which should be up and running in the second half of the year. At 130,000 square feet, the facility will be able to handle bioprocessing projects up to 1,000 liters in scale and crank out “metric tons” of drug substance, Just has said. 

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...